Project Grant R16DA066477
Award Date 8/1/26
Completion Date 5/31/30
Dollars Obligated $148K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Huntington, WV 25755, USA
Similar Awards
- The National Institute on Drug Abuse awarded The Johns Hopkins University $233,250 under the Drug Use and Addiction Research Programs (CFDA 93.279) on September 1, 2026, for a community-based mixed-methods assessment of medetomidine and adulterated fentanyl withdrawal. The research characterizes how people who use drugs recognize and respond to medetomidine in local drug supplies, describes medetomidine withdrawal experiences, and develops transferable methods for rapid adulterant...
- The National Institute on Drug Abuse awarded Wake Forest University Health Sciences $100,228 on November 7, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research investigating the role of synaptogyrin-3 in methamphetamine self-administration and dopamine dysfunction. The project examines synaptogyrin-3, a synaptic vesicle protein hypothesized to regulate dopamine release and uptake in the brain's reward circuitry. The research tests whether viral...
- The National Institute on Drug Abuse awarded New York University $103,607 on August 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct dissertation research on polysubstance use patterns and their associations with methadone maintenance treatment receipt and discontinuation among people who use drugs in New York State. The research uses a mixed-methods approach guided by the Social Ecological Model to identify latent polysubstance use patterns through urine...
- The National Institute on Drug Abuse awarded The University of Kentucky Research Foundation $2.175 million on September 30, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a randomized controlled clinical trial evaluating non-abstinence treatment outcomes for methamphetamine use disorder. The trial will enroll 200 treatment-seeking individuals with methamphetamine use disorder and randomly assign them to two groups: one receiving financial incentives...
- The National Institute on Drug Abuse awarded Oklahoma Medical Research Foundation $648,389 on February 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate cell type-specific neurotensin signaling in methamphetamine use disorder. The research combines intravenous methamphetamine self-administration in genetically-modified mice, brain slice electrophysiology, and virus-induced expression of designer ligand-sensitive proteins to determine how neurotensin...
- The National Institute on Drug Abuse awarded the University of Oklahoma Health Sciences Center $116,664 on January 6, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support basic research examining neurotensin's effects on ventral tegmental area neuron physiology and methamphetamine use disorder. The research uses patch clamp electrophysiology and behavioral assessment techniques to investigate how neurotensin modulates reward behavior through its receptors NTR1 and...
- The National Institute on Drug Abuse awarded the University of Arkansas for Medical Sciences $686,648 on July 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct basic research on the abuse-related and neurocognitive consequences of halogenated arylcyclohexylamines. The recipient will synthesize novel halogenated arylcyclohexylamine (ACX) analogues of phencyclidine and ketamine, then characterize their behavioral pharmacology using rodent models of drug...
- The National Institute on Drug Abuse awarded the Johns Hopkins University $2,141,865 for Project Grant R01DA064510 on September 15, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant funds a mixed-methods study evaluating methadone dispensing in carceral facilities using a new regulatory pathway. In 2024, the Substance Abuse and Mental Health Services Administration clarified that any carceral facility registered with the Drug Enforcement Administration as a...
- The National Institute on Drug Abuse awarded New York University $547,333 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a mixed-methods study identifying state-level implementation strategies for expanding access to extended take-home methadone doses in opioid treatment programs. The award funds a phased R61/R33 project examining how state agencies—including state opioid treatment authorities and Medicaid agencies—are facilitating adoption of...
- The National Institute on Drug Abuse awarded Yale University $641,138 on June 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a study examining methadone dose-associated risks and outcomes in opioid use disorder treatment, with particular focus on aging adults. The research leverages a national cohort of approximately 54,000 patients receiving care in the Department of Veterans Affairs, derived from the Veterans Aging Cohorts Study's national cohort...